SeaStar Medical Holding Corporation reported its financial results for the first quarter of 2026, revealing a net revenue of $495,000, a significant increase of 69% compared to $293,000 in the same period last year. The company attributed this growth primarily to increased adoption of its QUELIMMUNE therapy, which is the only FDA-approved treatment for pediatric patients with acute kidney injury due to sepsis. Despite the revenue increase, SeaStar recorded a net loss of $3.5 million for the quarter, slightly improved from a loss of $3.8 million in the first quarter of 2025.
The company's total assets decreased to $11.3 million as of March 31, 2026, down from $14.2 million at the end of 2025. This decline was primarily due to a reduction in cash reserves, which fell to $9.3 million from $12 million. SeaStar's accumulated deficit also increased to $155.2 million, reflecting ongoing operational losses. The company reported total operating expenses of $4.1 million, a slight decrease from $4.2 million in the prior year, with research and development expenses accounting for $2.3 million, down from $2.4 million.
In terms of strategic developments, SeaStar continues to focus on the commercialization of QUELIMMUNE while also conducting a pivotal clinical trial for its adult Selective Cytopheretic Device (SCD) therapy. The company has received multiple Breakthrough Device Designations from the FDA, which are expected to expedite the regulatory approval process for various indications. As of March 31, 2026, SeaStar had 17 employees, consistent with its headcount from the previous quarter.
Looking ahead, SeaStar faces significant challenges regarding its liquidity and ability to fund ongoing operations. The company has indicated that its current cash reserves may not be sufficient to cover operational costs for the next 12 months, raising substantial doubt about its ability to continue as a going concern. To address this, SeaStar plans to seek additional capital through equity or debt financing, although it acknowledges that such funding may not be available on favorable terms. The company’s future revenue generation will heavily depend on the successful rollout of QUELIMMUNE and the development of its adult SCD therapy.
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation develops extracorporeal medical devices targeting hyperinflammation and organ failure. Its flagship product, the Selective Cytopheretic Device (SCD), modulates immune cells to treat acute and chronic inflammatory conditions, including acute kidney injury, cardiorenal syndrome, and liver failure. The company focuses on regulatory approval, clinical trials, and strategic partnerships to commercialize its innovative, organ-agnostic therapy for critically ill patients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.